Syneron Medical to Report Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017
IRVINE, Calif., Jan. 30, 2017 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, today announced that it will release fourth quarter and full year 2016 financial results before the market opens on Wednesday, February 15, 2017. The earnings release will be available on Syneron's website at www.investors.syneron.com.
Syneron management will host a conference call and a live webcast at 8:30 a.m. (ET) on the same day. A question & answer session will follow management's discussion of events in the fourth quarter and full year 2016.
Investors and analysts may participate in the conference call using the following dial-in numbers:
US (toll free):
The conference passcode for both is 2212875.
Investors and other interested parties can also access a live webcast of the conference call through the Investor Relations page on Syneron's website at www.investors.syneron.com. Please log-in at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website.
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, women's intimate wellness treatments, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, CO2RE, CO2RE Intima, Profound and elōs Plus.
Founded in 2000, the company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SOURCE Syneron Medical Ltd.
For further information: Hugo Goldman, Chief Financial Officer, + 972 73 244 2283, Email: firstname.lastname@example.org | Zack Kubow, The Ruth Group, 646-536-7020, Email: email@example.com